NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Sunshine Biopharma, Inc. (SBFM) Stock Analysis

Sunshine Biopharma, Inc. (SBFM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SBFM

$0.22

−$0.00 (−2.09%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SBFM with… →

SBFM Key Statistics

As of Oct 21, 2026
Trading
Open
$0.23
Previous Close
$0.22
Day's Range
0.22–0.23
52-Week Range
0.19–23.20
Volume
335.09K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.35
Valuation
Market Cap
$3.19M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
0.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.45
Financials (FY)
Revenue (FY)
$36.31M+4.11%
Net Income (FY)
−$5.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
−16.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.82M
1-Year Return
−98.88%
Dividend and dates
Avg Volume
5.56M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SBFM closed at $0.22, −98.88% over 1 year.

Sunshine Biopharma, Inc. (SBFM) has a market capitalization of $3.19M.

In fiscal 2025, SBFM reported revenue of $36.31M.

SBFM Stock Return by Calendar Year

Sunshine Biopharma, Inc. (SBFM) return since Feb 2022: what $10,000 became

1 year
$10,000 $112
−98.88%
3 years
$10,000 $0.36
−99.996%
Since Feb 2022
$10,000 $0.05
−99.9995%

If you had invested $10,000 in Sunshine Biopharma, Inc. (SBFM) at the close on February 15, 2022, the earliest close on record here, it would have been worth $0.05 at the close on October 21, 2026: −99.9995% in total, −92.80% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−98.25%
2025−59.00%
2024−99.45%
2023−57.50%
2022 (partial year)−73.22%

As of October 21, 2026.

SBFM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$36.31M−$5.98M−16.5%
2024$34.87M−$5.13M−14.7%
2023$24.09M−$4.51M−18.7%
2022$4.35M−$26.74M−615.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$36.31M$12.26M−$4.48M−$5.98M−16.5%
2024$34.87M$10.67M−$5.81M−$5.13M−14.7%
2023$24.09M$8.34M−$4.79M−$4.51M−18.7%
2022$4.35M$1.70M−$8.67M−$26.74M−615.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SBFM Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricSBFMDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.092.100.0x the median
Profit margin−16.50%−8.14%8.4 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sunshine Biopharma, Inc. (SBFM) is capitalised at $3.19M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 50.

SBFM last closed at $0.22 on October 21, 2026. That is $0.00 (−2.09%) against the previous close. Over the past 52 weeks the price has ranged from $0.19 to $23.20. The latest close sits 15.81% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $36.31M. Against the prior fiscal year total of $34.87M, that is a change of +4.11%. The same year closed with a net loss of $5.98M. The reported profit margin is −16.5%. That is 8.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −9.45.

Across the 4 fiscal years on file, revenue moves from $4.35M in 2022 to $36.31M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 0. Measured against sales, the shares trade at 0.09 times revenue. On price-to-sales that is 0 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 1.35. Daily returns over the trailing 4 years annualize to a volatility of 145.28%. Over the trailing twelve months the total return is −98.88%. Measured over 3 years, that is −96.70% a year compounded.

Growth & Income

No dividend is on file for SBFM.

So far in 2026 the total return is −98.25%. The strongest complete calendar year on file is 2023 at −57.50%; the weakest is 2024 at −99.45%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

Sunshine Biopharma, Inc. (SBFM) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sunshine Biopharma, Inc. SBFM $3.19M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Sunshine Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Visit website →